Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo (intranasal saline) Clear all
Completed Phase 1 Interventional

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

NCT01533519
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Neuropeptide Y
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

NCT03245762
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Week to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional

Intranasal Civamide for Episodic Cluster Headache

NCT00069082
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Civamide (Zucapsaicin), Sodium Chloride
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Directed Topical Drug Delivery for Treatment for PASC Hyposmia

NCT05970731
View directory record Official record
Conditions
Post Acute Sequelae Covid-19 Hyposmia
Interventions
Beclomethasone, Placebo, Microsponge
Drug · Other · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Neural Correlates of Hypoalgesia Driven by Observation

NCT03897998
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo
Interventions
Naloxone, Saline
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse

NCT03539887
View directory record Official record
Conditions
Suicidal Ideation, Depression, Alcohol Abuse
Interventions
Intranasal ketamine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

NCT01614093
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 54 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Biology of Resilience

NCT01011465
View directory record Official record
Conditions
Oxytocin, Placebo
Interventions
intranasal oxytocin, Placebo, Social support, No Social Support
Drug · Behavioral
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
22 Years to 65 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2012 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin, Emotions and Mirror Neurons

NCT02228031
View directory record Official record
Conditions
Social Cognition, Expressed Emotion
Interventions
Oxytocin, Placebo
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults

NCT03473002
View directory record Official record
Conditions
Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
Interventions
Placebo, SeVRSV Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Effects of Oxytocin Nasal Spray on Social Affiliation

NCT00663039
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

NCT04785794
View directory record Official record
Conditions
Influenza Vaccine
Interventions
Sing2016 M2SR H3N2 influenza vaccine, Placebo
Biological · Other
Lead sponsor
FluGen Inc
Industry
Eligibility
50 Years to 85 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin, Alcohol Craving, and Intimate Partner Aggression

NCT03046836
View directory record Official record
Conditions
Alcohol Use
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine

NCT04960397
View directory record Official record
Conditions
H3N2 Influenza
Interventions
Placebo, Sing2016 M2SR H3N2
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Iowa City, Iowa • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oxytocin as Adjunctive Treatment of Schizophrenia

NCT01568528
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin, Placebo, Control
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Withdrawn Not applicable Interventional

Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department

NCT02517931
View directory record Official record
Conditions
Postdural Puncture Headache
Interventions
Sphenopalatine Ganglion Block, Placebo
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults

NCT05397119
View directory record Official record
Conditions
Influenza, Pandemic
Interventions
BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Phase IIb Study of Intranasal Glutathione in Parkinson's Disease

NCT02424708
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Reduced Glutathione 100mg, Reduced Glutathione 200mg, Placebo
Drug
Lead sponsor
Bastyr University
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Kenmore, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 3 Interventional

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

NCT05077917
View directory record Official record
Conditions
COVID-19 Pneumonia, COVID-19 Respiratory Infection, Pneumonia, Viral
Interventions
Cromolyn Sodium, Placebo
Drug · Other
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

NCT05736835
View directory record Official record
Conditions
COVID-19
Interventions
CVXGA
Biological
Lead sponsor
CyanVac LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
San Diego, California • Boise, Idaho • Sioux City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

NCT02415556
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Regular Human Insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 2, 2026, 2:27 AM EDT